These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1147 related items for PubMed ID: 22956068

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.
    J Clin Oncol; 2008 May 10; 26(14):2373-8. PubMed ID: 18413639
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E.
    Clin Oncol (R Coll Radiol); 2012 Apr 10; 24(3):183-9. PubMed ID: 21958729
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, Rogers K, Arnold B, Eaton A, Catalano J, McCormick B, Powell S, Ho A.
    Ann Surg Oncol; 2012 Nov 10; 19(12):3762-70. PubMed ID: 22576064
    [Abstract] [Full Text] [Related]

  • 7. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM, Sreedhara M, Chen YH, Bellon JR, Punglia RS, Wong JS, Harris JR, Brock JE.
    Int J Radiat Oncol Biol Phys; 2012 Mar 15; 82(4):e581-6. PubMed ID: 22208975
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma].
    Wang SY, Peng DF, Cai ZG, Zhang RZ, Yao TJ, Zhang H, Yang M, Dong HM.
    Zhonghua Zhong Liu Za Zhi; 2008 Mar 15; 30(3):203-6. PubMed ID: 18756937
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
    Pugliese MS, Karam AK, Hsu M, Stempel MM, Patil SM, Ho AY, Traina TA, Van Zee KJ, Cody HS, Morrow M, Gemignani ML.
    Ann Surg Oncol; 2010 Apr 15; 17(4):1063-8. PubMed ID: 20033325
    [Abstract] [Full Text] [Related]

  • 13. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun 15; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC, Ampil F, Burton G, Li BD, Chu QD.
    Surgery; 2010 Aug 15; 148(2):386-91. PubMed ID: 20580045
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
    Cefaro GA, Genovesi D, Trignani M, DI Nicola M.
    Anticancer Res; 2014 Mar 15; 34(3):1207-12. PubMed ID: 24596361
    [Abstract] [Full Text] [Related]

  • 18. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z, Thoms J, Ghosh S, Hanson J, Deschênes J, Sabri S, Abdulkarim B.
    Breast Cancer Res Treat; 2010 Nov 15; 124(1):187-94. PubMed ID: 20814819
    [Abstract] [Full Text] [Related]

  • 19. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P, Xu BH, Ma F, Li Q, Yuan P, Wang JY, Zhang P.
    Zhonghua Zhong Liu Za Zhi; 2011 May 15; 33(5):381-4. PubMed ID: 21875471
    [Abstract] [Full Text] [Related]

  • 20. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
    Cell Biol Int; 2008 Jun 15; 32(6):698-707. PubMed ID: 18296077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.